Current Treatment Options Guided by Molecular Classification in Endometrial Cancer.

doi:10.1007/s11864-026-01409-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Current Treatment Options Guided by Molecular Classification in Endometrial Cancer.

Current treatment options in oncology - 27 Aug 2026

Zhou Qingyu, Fu Wenxiu, Zhang Qianshuo, Tian Xiaolu, Zhang Zhengmao

Abstract excerpt

OPINION STATEMENT: In our view, molecular classification should guide, but not independently determine, treatment for endometrial cancer. The four major molecular subtypes-POLE-mutated (POLEmut), mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H), p53-abnormal/copy-number-high (p53abn/CNH), and no specific molecular profile/copy-number-low (NSMP/CNL)-should be interpreted together with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Decision-Making
Share to Combined Modality Therapy
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Source

Open in PubMed

Identifiers

PMID: 42658373
DOI: 10.1007/s11864-026-01409-w

Genes

POLE
WEE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.